Brain HealthAAAgingNCT07466290
L-serine and Strength Training in the Elderly
A study testing Strength training and L-serine supplementation in people with Brain Health and Longevity, run by University of Vienna at 1 site in Austria.
Trial summary
This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people. Healthy, independent women and men aged 65 to 85 are eligible to participate. Read more about this study
- Who is it for?
- Ages 65 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Brain Health, Longevity, Cognitive Performance
- What is being tested?
- Strength training and L-serine supplementation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 126 participants
- Where
- 1 siteAustria
- Study dates
- Mar 2026to Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 85 years
- All sexes
- Healthy volunteers accepted
- Older adult
Who may be able to join
- Men and women between the ages of 65 and 85
- Mini-Mental-State >23
- Independently mobile, without aids (walker, cane, etc.)
Who cannot join
- Chronic diseases that contraindicate medical training therapy
- Regular strength training (>1x/week) in the last 6 months before confinement
- Frailty Index ≥ 3
- Lack of written consent to test physical performance
- Regular use of Cortison-containing medications or Antibiotika
- MR-specific exclusion criteria: claustrophobia, metal equipment or other magnetic Material in or on the body
- Non-compliance with the study protocol: <70% of the planned L-serine administration, <70% of the strength training
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people.
Healthy, independent women and men aged 65 to 85 are eligible to participate. Participants will be randomly assigned to one of three groups: placebo, L-serine, or L-serine combined with strength training.
Cognitive tests, physical performance tests, and blood and brain tests will be conducted over a period of 48 weeks. The aim is to gain a better understanding of how nutrition and exercise can contribute to healthy aging.
Read the detailed description
The study is a randomized, controlled, double-blind intervention study with three parallel groups of healthy older adults (aged 65-85). It investigates the effects of L-serine supplementation with and without accompanying strength training on cognitive, neural, molecular, and functional parameters over 48 weeks.
The primary endpoint is the change in cognitive performance, measured using the composite RBANS score. Secondary endpoints include structural and functional brain parameters (MRI, EEG), psychosocial parameters, markers of oxidative stress and immune function, as well as physical performance and muscle mass.
- Conditions
- Brain Health, Longevity, Cognitive Performance, Strength Training Effects, Healthy Ageing, Ageing
- Being tested
- Strength training, L-serine supplementation, Control (cornstarch)
- Keywords
- Healthy Ageing, Brain ageing, Older adults, L-serine supplementation, Resistance training, Cognitive function, Cognitive ageing, Memory, Hippocampus, Magnetic resonance imaging, Electroencephalography, Brain connectivity, Muscle strength, Synaptic plasticity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Strength trainingBehavioural
Structured strength training 2x/week
L-serine supplementationDietary supplement
L-serine supplementation 6g/day
Control (cornstarch)Dietary supplement
Placebo 6g cornstarch/day, No strength training
| Study group | Role | What they receive |
|---|---|---|
| L-serine and strength training | Experimental | The L-serine and training group (LSERTRAIN) receives an L-serine supplement at a dose of 6 g/day over the entire study period (48 weeks). Receives: Behavioral: Strength training; Dietary Supplement: L-serine supplementation |
| L-serine supplementation | Active comparator | The L-serine group (LSER) receives an L-serine supplement at a dose of 6 g/day over the entire study period (48 weeks). Receives: Dietary Supplement: L-serine supplementation |
| Control | Placebo comparator | The control group (PLA) receives a placebo (cornstarch) throughout the entire study period (48 weeks) Receives: Dietary Supplement: Control (cornstarch) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in cognitive performance measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Global cognitive performance will be assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a standardized neuropsychological test battery that evaluates multiple cognitive domains including memory, attention, language, and visuospatial abilities.
The primary outcome is the RBANS Total Scale Index score, which summarizes performance across the RBANS cognitive domains. RBANS index scores are standardized scores with a mean of 100 and a standard deviation of 15, typically ranging from approximately 40 to 160. Higher scores indicate better cognitive performance.
Measured: Baseline, 18 weeks and 48 weeks of intervention
Secondary outcomes (30)
Change in cognitive domain performance measured by index scores of RBANS
The RBANS provides standardized index scores (mean = 100, standard deviation = 15) that typically range from approximately 40 to 160, with higher scores indicating better cognitive performance. The following RBANS domain indices will be evaluated: Immediate Memory Index, Visuospatial/Constructional Index, Language Index, Attention Index, and Delayed Memory Index.
Measured: Baseline, 18 weeks and 48 weeks of intervention
Change in hippocampal volume measured by magnetic resonance imaging (mm³)
Measured: Baseline and 48 weeks of intervention
Change in hippocampal functional connectivity measured by functional magnetic resonance imaging
Measured: Baseline and 48 weeks of intervention
Change in oscillatory brain activity measured using electroencephalography
Measured: Baseline, 18 weeks and 48 weeks of intervention
Change in hippocampal neurometabolite concentrations measured using single voxel magnetic resonance spectroscopy
Measured: Baseline, 18 weeks and 48 weeks of intervention
Change in lower limb muscle strength (isokinetic torque, dominant leg)
Concentric isokinetic peak torque (in newton meters, Nm) will be assessed for knee extension, knee flexion, and hip extension and flexion using an Isoforce dynamometer (TUR GmbH, Hohen Neuendorf, Berlin).
All isokinetic measurements will be performed on the dominant leg and with 4 consecutive repetitions at maximal effort of extension and flexion.
Testing the knee will be performed over a range of motion (ROM) of 20 degrees-100 degrees at angular velocities of 60 degrees/s , and 180 degrees/s.
Testing the hip will be performed over a range of motion (ROM) of 20 degrees- 90 degrees at angular velocities of 60 degrees/s , and 180 degrees/s.
The minimum possible torque is 00 Nm; higher values indicate better muscle strength.
Measured: Baseline, 18 weeks and 48 weeks of intervention
Rate of torque development (Nm/s) will be measured at a joint angle of 60 degrees flexion (knee) and 40 degrees flexion (hip).
Measured: Baseline, 18 weeks and 48 weeks of intervention
Change in maximum and total work (J) of knee and hip flexion and extension
Measured: Baseline, 18 weeks and 48 of intervention
Position of peak torque and maximum range of motion (deg.)
Measured: Baseline, 18 weeks and 48 weeks of intervention
Change in time to peak torque and time from peak to relaxation (sec.) during knee and hip extension and flexion
Measured: Baseline, 18 weeks and 48 weeks of intervention
Mean power (W) in knee and hip extension and flexion
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change in isometric handgrip strength
Isometric handgrip strength will be measured in kilograms (kg) using a JAMAR-compatible handgrip dynamometer adjustable to different grip widths. Testing will be performed seated. Each trial consists of a maximal isometric contraction held for 4-5 seconds; two trials will be conducted with the dominant and subsequently with the non-dominant hand, with 1-2 minutes rest between trials. The minimum possible value is 00 kg; higher values indicate better grip strength. Results will be recorded per trial; the analysis will use the highest value from the two trials (peak grip strength, kg).
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change in upper extremity functional performance measured by the 30-Second Arm Curl Test
The 30-Second Arm Curl Test assesses the number of full elbow-flexion repetitions completed in 30 seconds with a standardized dumbbell while seated.
Women use a 5 lb (2.3 kg) dumbbell; men use an 8 lb (3.6 kg) dumbbell. Participant sits upright near the front edge of a chair without armrests, back straight, feet flat on the floor, holding the dumbbell in the dominant hand with a supinated grip. After instruction and demonstration, the participant performs 2-3 practice repetitions. Following a 60-second rest, the timed test begins on the assessor's signal. The starting position is full elbow extension (down); the end position is full elbow flexion (up). Count only repetitions that complete the full range of motion (ROM). A repetition initiated in the final second (second 30) is counted as valid if more than 50% of the ROM is completed.
Minimum possible value is 0 repetitions; there is no predefined maximum.
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change in upper-body flexibility (Back Scratch Test)
The Back Scratch Test assesses shoulder, shoulder-girdle, and thoracic spine flexibility. While standing, one hand is placed over the shoulder and down between the shoulder blades; the other hand reaches up the back. The linear distance between the tips of the middle fingers is measured along the spine using a tape measure.
Record the distance in centimeters (cm) with sign convention: positive values indicate fingertip overlap; zero indicates fingertips just touch; negative values indicate a gap between fingertips. There is no predefined minimum or maximum (values can range from negative to positive depending on flexibility and anthropometrics). Higher (more positive) values indicate better flexibility.
Back Scratch distance (cm), dominant side (specify side assessed in the protocol). Use the same side and method at all time points.
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change in Lower body flexibility (Chair Sit and Reach Test)
The participant sits at the front edge of a stable chair placed against a wall (seat height approximately 45-46 cm). One leg is flexed at the knee with the foot flat on the floor; the other leg is extended at the knee with the ankle dorsiflexed to approximately 90 degrees. With the hands stacked (middle fingertips aligned), the participant inhales, then exhales while hinging at the hips to reach forward toward the toes of the extended leg, avoiding bouncing; the back stays straight and the head upright. The maximal position is held for about 2 seconds. The linear distance between the tip of the middle finger and the toes of the extended leg is measured along the lower limb/foot.
Record the distance (cm) using the following convention-0 cm if fingertips just touch the toes; negative values if the fingertips do not reach the toes (gap); positive values if the fingertips reach past the toes (overlap). Perform two trials per leg; record the best value per leg.
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change in lower extremity functional muscular performance measured by the 30-Second Chair Stand Test
The 30-Second Chair-Stand Test assesses functional muscular performance (strength × speed) of the lower extremities.
Stable, armless chair at approximately 46 cm seat height, placed against a wall to prevent movement. Participants wear non-slip, flat footwear or are barefoot. Participant sits upright, feet flat on the floor, arms crossed over the chest. On the assessor's signal, the participant stands up fully (knee and hip extension) and sits down as many times as possible within 30 seconds without using the arms. Count only full stand-sit cycles completed through the full range of motion (ROM). A repetition initiated in the final second (second 30) is counted as valid if more than 50% of the ROM is completed.
Number of valid chair-stands completed in 30 seconds. Minimum possible value is 0 repetitions; there is no predefined maximum. Higher values indicate better lower-extremity functional performance.
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Mobility and dynamic balance (Stand Up and Go Test)
The Stand Up and Go Test assesses dynamic lower extremity power, dynamic balance, and overall functional mobility/coordination.
Stable chair placed against a wall, seat height approximately 43 cm; a cone/marker placed 2.4 m from the front edge of the chair; clear, unobstructed path.
Participant starts seated, back upright, feet flat on the floor. On the assessor's signal, the participant stands up, walks 2.4 m to the cone, turns around the cone, walks back to the chair, and sits down again. Timing begins on the start signal and stops when the participant is fully seated. Testing is performed in usual footwear; use of any assistive device (if permitted) should be consistent across visits and recorded.
Time to complete the task, measured in seconds (s) to at least 0.1 s precision. Minimum possible value is 0 s; there is no predefined maximum. Lower times indicate better mobility and balance (i.e., higher values indicate worse performance).
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change in body composition measured by bioelectrical impedance analysis
Body composition will be assessed using bioelectrical impedance analysis (seca Hamburg seca mBCA515), including measures of fat mass, lean body mass, body mass, and body water .
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change in waist, abdominal, hip circumference (cm)
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change in oxidative stress marker such as malondialdehyde
The investigators will consider changes in plasma concentrations of oxidative stress marker such as malondialdehyde.
Measured: Baseline, 18 weeks and 48 weeks of intervention
Change from baseline in inflammatory marker (e.g. IL-6, TNF-alpha)
The investigators will consider changes in plasma concentrations of inflammatory markers such as Interleukin 1 (IL-1), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-alpha
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in RNA and DNA gene expression
RNA and DNA gene expression will be assessed in response to the interventions.
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in chromosomal damage (number of micronuclei/1000 binucleated cells)
Chromosomal damage will be assessed in lymphocytes in response to the interventions.
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in the composition of gut-microbiota
Gene sequencing of the 16S rRNA on the stool samples are performed to identify the microbes down to genus level as well as the microbial diversity and relative abundance.
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in stool short-chain fatty acids (SCFAs)
The stool short-chain fatty acids (SCFAs) will be extracted and quantitatively analysed by gas chromatography.
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in the metabolomic response
The metabolomic response (ie all metabolites) to the interventions will be analyzed using both nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques. Patterns of metabolites will be evaluated with statistical techniques, ie discriminant analysis and principal component analysis.
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in the amino acid pattern
The plasma amino acid pattern will be assessed with HPLC-MS.
Measured: Baseline, 18 weeks, and 48 weeks of intervention
Nutritional habits
Evaluation of potential changes in nutritional habits (24 hours dietary recall) with GloboDiet
Measured: Baseline, 18 weeks and 48 weeks of intervention
Change in sleep quality measured by the Pittsburgh Sleep Quality Index
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI) questionnaire. The PSQI global score ranges from 0 to 21, with higher scores indicating worse sleep quality.
Measured: Baseline, 18 weeks, and 48 weeks
Change in quality of life measured by the World Health Organization Quality of Life Questionnaire
Quality of life will be assessed using the World Health Organization Quality of Life Questionnaire (WHOQOL). Scores range from 0 to 100, with higher scores indicating better perceived quality of life.
Measured: Baseline, 18 weeks, and 48 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2026
- Study startMar 2026 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain HealthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 126 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Vienna
- Sponsor type
- University, hospital or other
- Collaborators
- Medical University of Vienna
- Responsible party
- Principal investigator, Karl-Heinz Wagner, University of Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07466290
- Sponsor's protocol ID
- 01391
- Other IDs
- 10.55776/PIN359
- Acronym
- AAAging
- Status last verified
- Feb 2026
- First submitted
- 23 Feb 2026
- Last updated
- 12 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- L-serine and Strength Training in the Elderly
- ClinicalTrials.gov ID
- NCT07466290
- Acronym / sponsor ID
- AAAging / 01391
- Conditions
- Brain Health, Longevity, Cognitive Performance, Strength Training Effects, Healthy Ageing, Ageing
- Keywords
- Healthy Ageing, Brain ageing, Older adults, L-serine supplementation, Resistance training, Cognitive function, Cognitive ageing, Memory
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 126 participants (estimated)
- Lead sponsor
- University of ViennaUniversity, hospital or other
- Collaborators
- Medical University of Vienna
- Study start
- Mar 2026 (estimated)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 12 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people.
Healthy, independent women and men aged 65 to 85 are eligible to participate. Participants will be randomly assigned to one of three groups: placebo, L-serine, or L-serine combined with strength training.
Cognitive tests, physical performance tests, and blood and brain tests will be conducted over a period of 48 weeks. The aim is to gain a better understanding of how nutrition and exercise can contribute to healthy aging.
Detailed description
The study is a randomized, controlled, double-blind intervention study with three parallel groups of healthy older adults (aged 65-85). It investigates the effects of L-serine supplementation with and without accompanying strength training on cognitive, neural, molecular, and functional parameters over 48 weeks.
The primary endpoint is the change in cognitive performance, measured using the composite RBANS score. Secondary endpoints include structural and functional brain parameters (MRI, EEG), psychosocial parameters, markers of oxidative stress and immune function, as well as physical performance and muscle mass.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| L-serine and strength training | Experimental | Behavioral: Strength training, Dietary Supplement: L-serine supplementationThe L-serine and training group (LSERTRAIN) receives an L-serine supplement at a dose of 6 g/day over the entire study period (48 weeks). |
| L-serine supplementation | Active comparator | Dietary Supplement: L-serine supplementationThe L-serine group (LSER) receives an L-serine supplement at a dose of 6 g/day over the entire study period (48 weeks). |
| Control | Placebo comparator | Dietary Supplement: Control (cornstarch)The control group (PLA) receives a placebo (cornstarch) throughout the entire study period (48 weeks) |
Who may qualify
- Ages
- 65 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
Key inclusion criteria (3 listed)
- Men and women between the ages of 65 and 85
- Mini-Mental-State >23
- Independently mobile, without aids (walker, cane, etc.)
Key exclusion criteria (7 listed)
- Chronic diseases that contraindicate medical training therapy
- Regular strength training (>1x/week) in the last 6 months before confinement
- Frailty Index ≥ 3
- Lack of written consent to test physical performance
- Regular use of Cortison-containing medications or Antibiotika
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Strength trainingStructured strength training 2x/week | Behavioural | L-serine and strength training |
| L-serine supplementationL-serine supplementation 6g/day | Dietary supplement | L-serine and strength training, L-serine supplementation |
| Control (cornstarch)Placebo 6g cornstarch/day, No strength training | Dietary supplement | Control |
Primary outcome
Change in cognitive performance measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time frame: Baseline, 18 weeks and 48 weeks of intervention
Global cognitive performance will be assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a standardized neuropsychological test battery that evaluates multiple cognitive domains including memory, attention, language, and visuospatial abilities. The primary outcome is the RBANS Total Scale Index score, which summarizes performance across the RBANS cognitive domains. RBANS index scores are standardized scores with a mean of 100 and a standard deviation of 15, typically ranging from approximately 40 to 160. Higher scores indicate better cognitive performance.
30 secondary outcomes
Change in cognitive domain performance measured by index scores of RBANS
Time frame: Baseline, 18 weeks and 48 weeks of intervention
Change in hippocampal volume measured by magnetic resonance imaging (mm³)
Time frame: Baseline and 48 weeks of intervention
Change in hippocampal functional connectivity measured by functional magnetic resonance imaging
Time frame: Baseline and 48 weeks of intervention
Change in oscillatory brain activity measured using electroencephalography
Time frame: Baseline, 18 weeks and 48 weeks of intervention
Change in hippocampal neurometabolite concentrations measured using single voxel magnetic resonance spectroscopy
Time frame: Baseline, 18 weeks and 48 weeks of intervention
Change in lower limb muscle strength (isokinetic torque, dominant leg)
Time frame: Baseline, 18 weeks and 48 weeks of intervention
Rate of torque development (Nm/s) will be measured at a joint angle of 60 degrees flexion (knee) and 40 degrees flexion (hip).
Time frame: Baseline, 18 weeks and 48 weeks of intervention
Change in maximum and total work (J) of knee and hip flexion and extension
Time frame: Baseline, 18 weeks and 48 of intervention
Position of peak torque and maximum range of motion (deg.)
Time frame: Baseline, 18 weeks and 48 weeks of intervention
Change in time to peak torque and time from peak to relaxation (sec.) during knee and hip extension and flexion
Time frame: Baseline, 18 weeks and 48 weeks of intervention
Mean power (W) in knee and hip extension and flexion
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change in isometric handgrip strength
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change in upper extremity functional performance measured by the 30-Second Arm Curl Test
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change in upper-body flexibility (Back Scratch Test)
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change in Lower body flexibility (Chair Sit and Reach Test)
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change in lower extremity functional muscular performance measured by the 30-Second Chair Stand Test
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Mobility and dynamic balance (Stand Up and Go Test)
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change in body composition measured by bioelectrical impedance analysis
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change in waist, abdominal, hip circumference (cm)
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change in oxidative stress marker such as malondialdehyde
Time frame: Baseline, 18 weeks and 48 weeks of intervention
Change from baseline in inflammatory marker (e.g. IL-6, TNF-alpha)
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in RNA and DNA gene expression
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in chromosomal damage (number of micronuclei/1000 binucleated cells)
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in the composition of gut-microbiota
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in stool short-chain fatty acids (SCFAs)
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in the metabolomic response
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Change from baseline in the amino acid pattern
Time frame: Baseline, 18 weeks, and 48 weeks of intervention
Nutritional habits
Time frame: Baseline, 18 weeks and 48 weeks of intervention
Change in sleep quality measured by the Pittsburgh Sleep Quality Index
Time frame: Baseline, 18 weeks, and 48 weeks
Change in quality of life measured by the World Health Organization Quality of Life Questionnaire
Time frame: Baseline, 18 weeks, and 48 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Brain Health
Enrolling by invitationPhase 2
Tirzepatide and Organ-specific Biological Aging
Longevity, Preventive Medicine
Active, not recruiting
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
Dementia, Cognitive Impairment
Active, not recruiting
Community-Empowerment and Environmental Enrichment-based Co-management (CEEEC) Model and Mechanisms for Improving Health of Older Stroke Patients With Multimorbidity
Hypertension, Type 2 Diabetes Mellitus (T2DM)
Recruiting
Early Avocado Exposure on Development and the Gut Microbiome in American Hispanic Infants
Gut Microbiome, Neurocognitive Correlates of Eating Habits
Not yet recruitingObservational study
Vascular Health and Function in Cystic Fibrosis
Cystic Fibrosis, Endothelial Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Strength training and L-serine supplementation in people with Brain Health and Longevity, run by University of Vienna at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Karl-Heinz Wagner, Prof. (+43-1-4277-54930, karl-heinz.wagner@univie.ac.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in cognitive performance measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (time frame: Baseline, 18 weeks and 48 weeks of intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.